Phagos

Phagos isolates phages, sequences both phages and target bacteria, predicts their interactions with proprietary AI models and validates candidates at the bench and in real-world conditions.

The page explains what bacteriophages are, their historical use in phage therapy, and their potential future applications.

The model identifies microbial environments likely to contain undiscovered antibiotics.

For the World Economic Forum, Alexandros Pantalis explains why phage therapy needs a different kind of regulation, and what France’s platform approach to veterinary phage medicines could mean for other countries.

For the World Economic Forum, Alexandros Pantalis and Ithri Benamara explain how AI is bringing back phages, a century-old answer to resistant bacteria.

CAPHARD, Phagos’s phage-bacteria interaction model, is available on Hugging Face for querying bacterial genomes and ranking phages.

MINDS showcases AI that is already working in the real world. Phagos is one of 20 organizations in its second cohort, announced at the Forum’s Annual Meeting in Davos.

The Forum picked 100 early-stage companies from 28 countries for its 2025 cohort. Phagos is one of them, for using AI to match phages to the bacteria they kill.

Phagos aims to end bacterial disease by developing tools to analyze phage-bacteria interactions systematically.

Phagos creates foundation models trained on phage-bacteria interactions to identify phages effective against specific bacterial strains.

French startup **Phagos** applies **artificial intelligence** to discover new treatments that could replace traditional antibiotics. The company targets the growing challenge of antibiotic resistance by leveraging AI-driven research to identify potential alternatives. Phagos operates at the intersection of biotechnology and machine learning to accelerate drug discovery in this critical medical field.

Nov 2025ABC mediaNews article

Phagos secures $30 million in Series A funding to advance its mission against bacterial diseases. The round is co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with additional support from Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, and Station F. The investment underscores growing backing for Phagos’ antibacterial research and development efforts.

Oct 2025Tech MorningNews article

Phagos secures €25 million in Series A funding to advance bacteriophage-based treatments for bacterial infections in veterinary medicine. The company combines microbiology expertise with AI-driven discovery to develop phage therapies as an alternative to antibiotics. Phagos aims to leverage its regulatory progress to accelerate deployment of these targeted treatments for animals.

Oct 2025Microbiome Times MagazineNews article

Phagos secures $29 million in funding to advance its non-antibiotic treatment for livestock infections. The solution leverages bacteriophage therapy to combat bacterial resistance in animals. The company targets global markets where antibiotic use in farming faces increasing regulation.

Oct 2025AgFunderNewsNews article